Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Leflunomide: an unlikely trigger and mechanistically a beneficial drug for alopecia areata.

Literature DB >> 31332691

Leflunomide: an unlikely trigger and mechanistically a beneficial drug for alopecia areata.

Kabir Sardana¹, Aastha Gupta², Pulin Kumar Gupta³.

Abstract

Entities: Chemical Disease

Mesh：

Substances：
Isoxazoles
Leflunomide

Year: 2019 PMID： 31332691 DOI： 10.1007/s10067-019-04669-0

Source DB: PubMed Journal: Clin Rheumatol ISSN： 0770-3198 Impact factor: 2.980

Keyword Cloud
References

× No keyword cloud information.

13 in total

1. Third International Research Workshop on Alopecia Areata.

Authors: K J McElwee
Journal: J Invest Dermatol Date: 1999-05 Impact factor: 8.551

2. A novel mechanism of action of the immunomodulatory drug, leflunomide: augmentation of the immunosuppressive cytokine, TGF-beta 1, and suppression of the immunostimulatory cytokine, IL-2.

Authors: W W Cao; P N Kao; Y Aoki; J C Xu; R A Shorthouse; R E Morris
Journal: Transplant Proc Date: 1996-12 Impact factor: 1.066

3. Recalcitrant alopecia areata responsive to leflunomide and anthralin-Potentially undiscovered JAK/STAT inhibitors?

Authors: Kabir Sardana; Aastha Gupta; Ram K Gautam
Journal: Pediatr Dermatol Date: 2018-10-15 Impact factor: 1.588

4. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition.

Authors: Luzhou Xing; Zhenpeng Dai; Ali Jabbari; Jane E Cerise; Claire A Higgins; Weijuan Gong; Annemieke de Jong; Sivan Harel; Gina M DeStefano; Lisa Rothman; Pallavi Singh; Lynn Petukhova; Julian Mackay-Wiggan; Angela M Christiano; Raphael Clynes
Journal: Nat Med Date: 2014-08-17 Impact factor: 53.440

5. Alopecia areata occurring during anti-TNF therapy: a national multicenter prospective study.

Authors: Marie Tauber; Sébastien Buche; Pascal Reygagne; Jean-Marie Berthelot; François Aubin; Pierre-Dominique Ghislain; Jean-David Cohen; Pascal Coquerelle; Elisa Goujon; Denis Jullien; Hedia Brixi; Géraldine Jeudy; Xavier Guennoc; Antoine Martin; Emilie Brénaut; Emmanuel Hoppé; Antoine Bertolotti; Thomas Bardin; Emmanuel Delaporte; Matthieu Allez; Hervé Bachelez; Julien Seneschal; Manuelle Viguier
Journal: J Am Acad Dermatol Date: 2014-06 Impact factor: 11.527

Leflunomide: an unlikely trigger and mechanistically a beneficial drug for alopecia areata.

1. Third International Research Workshop on Alopecia Areata.

2. A novel mechanism of action of the immunomodulatory drug, leflunomide: augmentation of the immunosuppressive cytokine, TGF-beta 1, and suppression of the immunostimulatory cytokine, IL-2.

3. Recalcitrant alopecia areata responsive to leflunomide and anthralin-Potentially undiscovered JAK/STAT inhibitors?

4. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition.

5. Alopecia areata occurring during anti-TNF therapy: a national multicenter prospective study.

6. Reversible alopecia areata: a little known side effect of leflunomide.

Review 7. Drug-induced hair loss and hair growth. Incidence, management and avoidance.

8. Efficacy and safety of methotrexate in alopecia areata.

9. Drug-induced alopecia after dupilumab therapy.

10. Nivolumab-induced alopecia areata: A reversible factor of good prognosis?